We are live on ! Find out more
APLS

Apellis Pharmaceuticals
APLS

Delisted

APLS was delisted on the 13th of May, 2026.

Back to rankings

145 hedge funds and large institutions have $1.85B invested in Apellis Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 50 increasing their positions, 49 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

29% more call options, than puts

Call options by funds: $4.72M | Put options by funds: $3.67M

17% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 18

2% more funds holding

Funds holding: 142 → 145 (+3)

1.17% more ownership

Funds ownership: 81.03% → 82.2% (+1.2%)

2% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 49

7% less capital invested

Capital invested by funds: $2B → $1.85B (-$149M)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

Holders
145
Holders Change
+3
Holders Change %
+2.11%
% of All Funds
2.93%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.06%
New
21
Increased
50
Reduced
49
Closed
18
Calls
$4.72M
Puts
$3.67M
Net Calls
+$1.05M
Net Calls Change
-$424K

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$24.9M
2
Jennison Associates
Jennison Associates
New York
+$21.2M
3
APM
Avidity Partners Management
Texas
+$18.6M
4
JP Morgan Chase
JP Morgan Chase
New York
+$18M
5
Norges Bank
Norges Bank
Norway
+$16.1M

Top Sellers

Rank Fund Capital Flow
1
Fidelity International
Fidelity International
Bermuda
-$25.4M
2
SAM
Sectoral Asset Management
Quebec, Canada
-$25.1M
3
EP
Eversept Partners
New York
-$10.1M
4
Two Sigma Investments
Two Sigma Investments
New York
-$7.13M
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$6.87M
Name Holding Trade Value Shares
Change 		Change in
Stake
Wellington Management Group
1
Wellington Management Group
Massachusetts
$315M +$248K +8,297 +0.1%
BlackRock
2
BlackRock
New York
$180M -$5.87M -196,547 -3%
HA
3
HHLR Advisors
Cayman Islands
$152M – – –
Vanguard Group
4
Vanguard Group
Pennsylvania
$130M -$2.09M -69,824 -2%
T. Rowe Price Associates
5
T. Rowe Price Associates
Maryland
$89.9M -$1.48M -49,435 -2%
State Street
6
State Street
Massachusetts
$86.4M -$2.47M -82,655 -3%
Jennison Associates
7
Jennison Associates
New York
$85.6M +$21.2M +710,708 +33%
FCM
8
Farallon Capital Management
California
$68.6M +$747K +25,000 +1%
Citadel Advisors
9
Citadel Advisors
Florida
$66.4M +$24.9M +832,498 +61%
Victory Capital Management
10
Victory Capital Management
Texas
$64.7M +$5.41M +180,917 +9%
CAM
11
Cormorant Asset Management
Massachusetts
$56.3M -$5.98M -200,000 -10%
Goldman Sachs
12
Goldman Sachs
New York
$40.2M +$9.52M +318,550 +31%
CS
13
Candriam SCA
Luxembourg
$34.7M -$1.84M -61,533 -5%
BBA
14
Baker Bros. Advisors
New York
$27M – – –
Geode Capital Management
15
Geode Capital Management
Massachusetts
$26.5M +$356K +11,916 +1%
Two Sigma Advisers
16
Two Sigma Advisers
New York
$24.5M -$3.26M -109,000 -12%
Invesco
17
Invesco
Georgia
$21.9M +$4.62M +154,664 +27%
Northern Trust
18
Northern Trust
Illinois
$21.3M +$247K +8,276 +1%
JP Morgan Chase
19
JP Morgan Chase
New York
$20.3M +$18M +602,266 +595%
Norges Bank
20
Norges Bank
Norway
$19.4M +$16.1M +538,104 +514%
APM
21
Avidity Partners Management
Texas
$18.8M +$18.6M +623,300 New
FT
22
Fiduciary Trust
Massachusetts
$17.2M -$657K -22,000 -4%
Deutsche Bank
23
Deutsche Bank
Germany
$16.8M +$363K +12,144 +2%
VP
24
venBio Partners
California
$15.1M – – –
Point72 Asset Management
25
Point72 Asset Management
Connecticut
$13.5M +$7.14M +238,833 +115%
1
2 3 4 5

APLS Hedge Fund Activity: Q3 2020 in Review

145 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Apellis Pharmaceuticals (APLS) for Q3 2020, worth a combined $1.85B — down 7.4% from $2B a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new APLS positions and 18 closed out — a net gain of 3 holders — while 50 added to existing stakes and 49 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $24.9M. The largest seller was Fidelity International, cutting an estimated $25.4M.

  • 145 institutional investors held Apellis Pharmaceuticals (APLS) as of Q3 2020, up from 142 in Q2 2020.
  • Funds reported $1.85B of Apellis Pharmaceuticals stock for Q3 2020, down 7.4% quarter-over-quarter.
  • 21 funds opened new Apellis Pharmaceuticals positions in Q3 2020 and 18 closed out, a net change of +3 holders.
  • The largest Apellis Pharmaceuticals buyer in Q3 2020 was Citadel Advisors, an estimated $24.9M added.
  • The largest Apellis Pharmaceuticals seller in Q3 2020 was Fidelity International, an estimated $25.4M sold.

Based on aggregated 13F filings for Q3 2020.